NCT06614816View on ClinicalTrials.gov

Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years

PHASE3CompletedINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

February 10, 2019

Primary Completion Date

July 15, 2021

Study Completion Date

June 20, 2022

Conditions
Chickenpox Vaccines
Interventions
BIOLOGICAL

Oka strain varicella attenuated live vaccine

lyophilized powder, subcutaneous injection

Trial Locations (1)

223399

Huaiyin District Center for Disease Control and Prevention, Huaian

All Listed Sponsors
collaborator

Jiangsu CDC

UNKNOWN

lead

Southeast University, China

OTHER

NCT06614816 - Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years | Biotech Hunter | Biotech Hunter